Hemophilia Treatment Market Research Report: By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (Recombinant Coagulation Factor, Plasma-Derived Coagulation Factor, Desmopressin, Antifibrinolytic Agents), End User Forecast Till 2027

Hemophilia Treatment Market Overview: 

Hemophilia Treatment market will exhibit an above-average CAGR of 6.10% during 2018 to 2023.

Hemophilia is a genetic disorder that is generally hereditary where the patient’s blood lacks the required proteins that help in blood coagulation. The condition could be mild, moderate, and severe. However, the condition is generally diagnosed at the early stages in patients. A recent report says that over 400 babies are born with hemophilia each year and over 33,000 males were living with the condition in the United States. The early diagnosis of the condition is made possible since most of the babies born are tested immediately after they are born. Prenatal genetic testing is carried out for the fetuses inside the womb which helped to diagnose the condition.  

Due to the absence of a sufficient amount of blood-clotting proteins and factors, clotting of blood becomes difficult for the patients. The males possessing the condition are because of the X chromosome passed to them from their mother. The prevalent treatment given to hemophilia is Replacement therapy through which the missing protein, generally clotting factor VIII is administered into patients’ veins. For the patients who are diagnosed with a severe condition of Hemophilia, the major reasons are the presence of other rare complications of the condition and other health conditions. 

COVID 19 Analysis: 

The outbreak of COVID 19 has affected a huge population all over the globe. However, the people who are diagnosed with Hemophilia are very much prone to infectious diseases. Period before COVID also, the blood-borne viruses have severely targeted the Hemophilia patients. Hemophilia patients are advised to monitor their blood pressure and follow medical guidelines to ensure a good immune system. Hence the pandemic has increased the Hemophilia Treatment market value. 

In December 2020, four associations namely the World Federation of Hemophilia (WFH), the European Association for Hemophilia and Allied Disorders (EAHAD), European Hemophilia Consortium (EHC), and U.S. National Hemophilia Foundation (NHF) have combined and issued COVID vaccination guidelines for the Hemophilia patients which have also recommended to continue the treatment for Hemophilia after the COVID vaccination. Such constant guidance and recommendations have enhanced the Hemophilia Treatment market outlook during the pandemic. 

Market dynamics: 

Market drivers:

The increasing number of Hemophilia cases across the globe has been the primary factor that fuels the Hemophilia Treatment industry growth. In the year 2019, there were over 49,083 people diagnosed with bleeding disorders which have increased to 400,000 people in the year 2020-2021. Additionally, favorable government schemes in several countries like reducing the expenditure related to Hemophilia Treatment have impacted the market growth. 

The varied availability of therapies and medications has increased the demand for the Hemophilia Treatment market growth. Therapy of inhibitors, home therapy, free factor replacement, Antifibrinolytic medicines, gene therapy, and physical therapy are some of the commonly utilized therapies and medications used in Hemophilia treatment. These factors have created a huge positive impact on the Hemophilia Treatment market growth. 

Market opportunities: 

The increasing governmental schemes and aggressive campaigning has aided the growth of the Hemophilia Treatment market in recent years. Especially the medical guidelines according to the COVID vaccination has enhanced the treatment and facilities related to Hemophilia Treatment in recent years. The injectable administration is showcasing a growth rate of over 5% in recent years, owing to the increased life quality and enhance overall treatment witnessed in Hemophilia patients. 

The recent technologies and medications have created a revolution in the Hemophilia Treatment market outlook in recent years. Recent inventions have shown up to 80% of recovery from the symptoms of the condition and over 94% reduction in the annual bleeding rates. These factors have created a major opportunity for the Hemophilia Treatment industry growth. 

Market restraints: 

The higher costs associated with the recombinant products and the complications involved in the replacement therapies are currently hindering the growth of the Hemophilia Treatment industry.

Hemophilia patients who undergo the replacement therapies acquire complications like viral infections like hepatitis B and C or HIV. These adverse actions on treating the condition have impacted the growth of the Hemophilia Treatment industry.

The patients are capable of developing inhibitors that destroy the injected clotting factor before they start to work. The chances of developing these inhibitors in the patients with Severe Hemophilia A range between 20-30% and the chances in patients with hemophilia B ranges between 2-5%. These factors have also impacted the growth of the Hemophilia treatment industry. 

Market challenges: 

The increasing costs of the recombinant products and the overall treatment are considered as the primary challenge for the growth of Hemophilia treatment in recent years. The higher investment requirements in the R&D development and manufacturing processes are the primary reasons for the increasing costs of the treatment. 

Some of the therapies like gene therapy are yet to be approved for treating Hemophilia. The delays in the researches in the clinical trials are also imposing challenges for the growth of the Hemophilia Treatment market. 

Cumulative growth analysis: 

The recombinant coagulation factor concentrates have dominated the market with 52.91% in the year 2020. The growing research activities in gene therapies and various other methods are significantly increasing the demand for the Hemophilia Treatment market growth. The increasing government incentives towards the market and aggressive campaigns have also aided the growth of the Hemophilia Treatment industry. 

The Hemophilia Treatment industry registering a CAGR of 6.10% in the forecast period. The rising number of cases where bleeding occurs in joints has impacted the growth of the market in recent years. Joint bleeding is considered the major challenge in the market, owing to the higher chances of permanent damage of knee, ankle, or elbow joints. The development of inhibitors that slashes the efficacy of administrating drugs and medications is also becoming a major challenge in the Hemophilia Treatment industry in recent years. 

Value chain analysis: 

Hemophilia is a bleeding disorder that occurs if the individual’s blood clotting mechanism is damaged. The recent reports state that one in 5000 males are born with Hemophilia in the US, however, the poor economic condition of the country highly affects the treatment and access to the facility. A recent study shows that over 75% of Hemophilia patients are unable to access the treatments, due to which over 60% of patients are developing severity of the condition.  

Increasing awareness towards home therapies, effective precautions, and physical therapies have reduced the severity of the condition in several Hemophilia cases. Additionally, the inventions in the treatments and methodologies have increased the Hemophilia treatment market value in recent years. 

Segment overview: 

Based on diagnosis: 

• Replacement therapy


• Gene Therapy 

Based on treatment: 

• Plasma-derived coagulation factor concentrate


• Recombinant Coagulation Factor Concentrates


• Desmopressin


• Antifibrinolytic agents


• Gene therapy 

Based on the product: 

• Plasma-derived coagulation factor concentrates

• Factor VIII


• Factor IX


• Factor XIII


• Activated Prothrombin complex concentrate


• Von Willebrand factor






• Recombinant coagulation factor concentrates






• Factor VIII


• Factor IX


• Von willebrand factor






• Desmopressin


• Antifibrinolytic agents 

Based on distribution channel:

• Hospital pharmacy


• Retail pharmacy


• Others 

Regional analysis: 

Currently, North America is handling the Hemophilia treatment strategies better by increasing its partnerships and collaborations with leading market players. These strategies have impacted the market growth positively. Additionally, increasing awareness of the condition and the technological advances in the products and therapeutic methods have further fueled the growth of the Hemophilia treatment market in recent years in North America. 

Association of America has expanded its market growth by offering co-pay initiatives for the patients to acquire continuous treatment. Recently, the advancements in gene therapy that targets coagulation factors have impacted a huge impact on the Hemophilia treatment industry. Asia-pacific is expected to hold the second-largest position in the Hemophilia Treatment market outlook because of the increasing favorable reimbursement policies. Stats of China has declared that over 80% of the Hemophilia treatment done in the region has been covered under health insurance which accounted for more than USD 16,000 in the year 2012. Since then the favorable schemes have been rising in China. 

Competitive landscape: 

• Takeda Pharmaceutical Co., Ltd.,


• Sanofi S.A., Octapharma AG


• Swedish Orphan Biovitrum AB


• Baxter International Inc.


• Biogen Inc.


• Bayer AG


• CSL Behring


• Ferring B.V.


• Pfizer, Inc.


• Kedrion


• Novo Nordisk A/S


• F. Hoffmann-La Roche AG. 

Recent developments: 

Hemophilia Treatment has generally integrated the coagulation factor into the patients. The recent development of a lab version of coagulation factor VIII which is named as GreenGene F (beroctocog alfa) has gotten approval from the Chinese regulators. This coagulation factor is expected to be administrated into the patients’ by 2022 for control and prevention of Hemophilia A.  

The existing technology in liver transplantation and treating liver impairment has been recently utilized in Hemophilia treatment. The Hepastem technology which grows live cells in the healthy liver of the donor, which are then injected into the patients, is expected to make a huge difference in patients diagnosed with Hemophilia A and Hemophilia B where the gene therapy seems to be less effective.  

Report overview: 

This report has covered: 

• Market overview


• COVID -19 Analysis


• Market dynamics


• Cumulative growth analysis


• Value chain analysis


• Segment overview


• Regional analysis


• Competitive landscape


• Recent developments 

Segmentation Table: 

Based on diagnosis: 

• Replacement therapy


• Gene Therapy 

Based on treatment: 

• Plasma-derived coagulation factor concentrate


• Recombinant Coagulation Factor Concentrates


• Desmopressin


• Antifibrinolytic agents


• Gene therapy 

Based on the product: 

• Plasma-derived coagulation factor concentrates

• Factor VIII


• Factor IX


• Factor XIII


• Activated Prothrombin complex concentrate


• Von Willebrand factor






• Recombinant coagulation factor concentrates






• Factor VIII


• Factor IX


• Von willebrand factor






• Desmopressin


• Antifibrinolytic agents 

Based on distribution channel:

• Hospital pharmacy


• Retail pharmacy


• Others